ATE241345T1 - Neue verwendung von orexinrezeptorantagonisten - Google Patents

Neue verwendung von orexinrezeptorantagonisten

Info

Publication number
ATE241345T1
ATE241345T1 AT00903690T AT00903690T ATE241345T1 AT E241345 T1 ATE241345 T1 AT E241345T1 AT 00903690 T AT00903690 T AT 00903690T AT 00903690 T AT00903690 T AT 00903690T AT E241345 T1 ATE241345 T1 AT E241345T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
orexin receptor
new use
neuroprotectants
nausea
Prior art date
Application number
AT00903690T
Other languages
English (en)
Inventor
Elaine Alison Irving
Gareth John Sanger
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903284.9A external-priority patent/GB9903284D0/en
Priority claimed from GBGB9903282.3A external-priority patent/GB9903282D0/en
Priority claimed from GBGB9903278.1A external-priority patent/GB9903278D0/en
Priority claimed from GBGB9903265.8A external-priority patent/GB9903265D0/en
Priority claimed from GBGB9906061.8A external-priority patent/GB9906061D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE241345T1 publication Critical patent/ATE241345T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00903690T 1999-02-12 2000-02-10 Neue verwendung von orexinrezeptorantagonisten ATE241345T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9903284.9A GB9903284D0 (en) 1999-02-12 1999-02-12 Novel use
GBGB9903282.3A GB9903282D0 (en) 1999-02-12 1999-02-12 Novel use
GBGB9903278.1A GB9903278D0 (en) 1999-02-12 1999-02-12 Novel compounds
GBGB9903265.8A GB9903265D0 (en) 1999-02-12 1999-02-12 Novel use
GBGB9906061.8A GB9906061D0 (en) 1999-03-17 1999-03-17 Novel use
PCT/EP2000/001147 WO2000047284A2 (en) 1999-02-12 2000-02-10 Novel use of orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE241345T1 true ATE241345T1 (de) 2003-06-15

Family

ID=27517496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903690T ATE241345T1 (de) 1999-02-12 2000-02-10 Neue verwendung von orexinrezeptorantagonisten

Country Status (8)

Country Link
US (1) US6506774B1 (de)
EP (2) EP1150664B1 (de)
JP (1) JP2002536425A (de)
AT (1) ATE241345T1 (de)
AU (1) AU2548400A (de)
DE (1) DE60002984T2 (de)
ES (1) ES2199770T3 (de)
WO (1) WO2000047284A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2548400A (en) * 1999-02-12 2000-08-29 Smithkline Beecham Plc Novel use of orexin receptor antagonists
AU2001297807A1 (en) * 2000-12-20 2002-11-11 Sri International Modulators of the hypocretin system and methods of screening therefor
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
CA2557163C (en) 2004-03-01 2011-08-16 Idorsia Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US20160250224A1 (en) * 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
EP3223803A1 (de) * 2014-11-24 2017-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung eines ox1r-agonisten zur behandlung von entzündlichen darmerkrankungen
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (de) * 1995-05-05 1999-01-20 Human Genome Sciences Inc Humaner neuropeptidrezeptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) * 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
JP2003527302A (ja) * 1997-12-15 2003-09-16 スミスクライン ビーチャム パブリック リミテッド カンパニー 新規な神経ペプチドレセプターｈｆｇａｎ７２のリガンドおよびそのアゴニストまたはアンタゴニストを用いる治療方法
US6372757B1 (en) * 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
ATE314371T1 (de) * 1998-11-10 2006-01-15 Merck & Co Inc Spiro-indole als y5-rezeptor antagonisten
AU2548400A (en) * 1999-02-12 2000-08-29 Smithkline Beecham Plc Novel use of orexin receptor antagonists
EP1144409B1 (de) * 1999-02-12 2004-11-17 SmithKline Beecham plc Phenylharnstoff und phenylthioharnstoffderivate

Also Published As

Publication number Publication date
EP1150664A2 (de) 2001-11-07
WO2000047284A3 (en) 2000-12-14
WO2000047284A2 (en) 2000-08-17
DE60002984T2 (de) 2004-03-11
AU2548400A (en) 2000-08-29
DE60002984D1 (de) 2003-07-03
JP2002536425A (ja) 2002-10-29
EP1352651A3 (de) 2003-11-12
EP1352651A2 (de) 2003-10-15
ES2199770T3 (es) 2004-03-01
US6506774B1 (en) 2003-01-14
EP1150664B1 (de) 2003-05-28

Similar Documents

Publication Publication Date Title
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
IT1313625B1 (it) Derivati benzimidazolonici aventi affinita&#39; mista per i recettori diserotonina e dopamina.
DE69837606D1 (de) Cystein-reiche rezeptoren-train
ATE242243T1 (de) Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
AP2000001949A0 (en) 4-Benzyl piperidine alkysulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists.
ATE505190T1 (de) Azabicycloalkane als ccr5-modulatoren
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE60121609D1 (de) Modifiziertes polyolefinharz, modifizierte polyolefinharzzusammensetzung und ihre verwendung
DE50010677D1 (de) Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
SE9702773D0 (sv) Novel compounds
DE60002526D1 (de) Herstellung von Tricyclodecandicarbaldehyd, Pentacyclopentadecandicarbaldehyd und der entsprechenden Dimethanole
ATE194595T1 (de) Benzonitrile als 5-ht agonisten und antagonisten
PT885215E (pt) Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
DE69128941D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung der diabetischen nephropathie
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
DE60002984D1 (de) Neue verwendung von orexinrezeptorantagonisten
DE60024652D1 (de) Unkonjugiertes cyklisches polyencopolymer, kautschukzusammensetzung und verwendung
PT869955E (pt) As n-acil-2-substituidas-4-(substituidas com residuos benzimidazolilo ou imidapiridinilo)-piperidinas como antagonistas das taquicininas
PT923550E (pt) Derivados de acilaminoalcenileno-amida como antagonistas de nk1 e nk2
DE69740099D1 (de) Transdermale zusammenstellung mit serotoninrezeptor-antagonist
PT964863E (pt) Oxazolidinonas como antagonistas de 5-ht2a
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
BR0010843A (pt) Antagonistas de receptores de il-8
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties